SEC Form 10-Q filed by Rogers Corporation

10/25/24 1:51:21 PM ET

Major Chemicals

Industrials

Get the next $ROG alert in real time by email

rog-20240930

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 10-Q

_______________________________


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission file number 1-4347

_______________________________

ROGERS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

_______________________________


Massachusetts			06-0513860
(State or Other Jurisdiction of			(I. R. S. Employer Identification No.)
Incorporation or Organization)

2225 W. Chandler Blvd., Chandler, Arizona 85224-6155

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (480) 917-6000

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)	Name of each exchange on which registered
Capital Stock,	par value $1.00 per share	ROG	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The number of shares outstanding of the registrant’s capital stock as of October 21, 2024 was 18,660,557.

ROGERS CORPORATION

FORM 10-Q

September 30, 2024


TABLE OF CONTENTS
Part I – Financial Information
	Item 1.	Condensed Consolidated Financial Statements (Unaudited):
		Condensed Consolidated Statements of Operations	4
		Condensed Consolidated Statements of Comprehensive Income	5
		Condensed Consolidated Statements of Financial Position	6
		Condensed Consolidated Statements of Shareholders’ Equity	7
		Condensed Consolidated Statements of Cash Flows	8
		Notes to Condensed Consolidated Financial Statements	9
	Item 2.	Management’s Discussion and Analysis of Results of Operations and Financial Position	26
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
	Item 4.	Controls and Procedures	34

Part II – Other Information
	Item 1.	Legal Proceedings	35
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
	Item 5.	Other	35
	Item 6.	Exhibits	36
		Signatures	37

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Refer to “Forward-Looking Statements” in Item 2, Management’s Discussion and Analysis of Results of Operations and Financial Position for additional information.

ROGERS CORPORATION

Defined Terms(1)


Term			Definition
4th Amended Credit Agreement			4th Amended and Restated Credit Agreement, dated as of October 16, 2020, among Rogers Corporation, the lenders from time to time party hereto, JPMorgan Chase Bank, N.A., as Administrative Agent and HSBC Bank USA, National Association, Citibank, N.A., Citizens Bank, N.A., PNC Bank, National Association, Wells Fargo Bank, as Co-Syndication Agents
5th Amended Credit Agreement			5th Amended and Restated Credit Agreement, dated as of March 24, 2023, among Rogers Corporation, the lenders from time to time party hereto, JPMorgan Chase Bank, N.A., as Administrative Agent and HSBC Bank USA, National Association, Wells Fargo Bank, National Association, Citibank, N.A. and Citizens Bank, N.A., as Co-Syndication Agents
ADAS			Advanced driver assistance systems
AES			Advanced Electronics Solutions
APAC			Asia - Pacific
ASC			Accounting Standards Codification
ASU			Accounting Standards Update
EMEA			Europe, the Middle East and Africa
EMS			Elastomeric Material Solutions
ESPP			Employee Stock Purchase Plan
EURIBOR			Euro Interbank Offered Rate
EV			Electric vehicles
Exchange Act			Securities Exchange Act of 1934, as amended
FASB			Financial Accounting Standards Board
GAAP			Accounting principles generally accepted in the United States
HEV			Hybrid electric vehicles
LIBOR			London Interbank Offered Rate
NYFRB			Federal Reserve Bank of New York
OECD			Organization for Economic Co-operation and Development
R&D			Research and development
RIC			Rogers Inoac Corporation
RIS			Rogers Inoac Suzhou Corporation
SEC			U.S. Securities and Exchange Commission
SG&A			Selling, general and administrative
SOFR			Secured Overnight Financing Rate
SONIA			Sterling Overnight Index Average
TIBOR			Tokyo Interbank Offered Rate
Union Plan			Rogers Corporation Employees’ Pension Plan
U.S.			United States of America

(1)Certain terms used within this Form 10-Q are defined in the table above.

Part I – Financial Information

Item 1. Financial Statements

ROGERS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(Dollars and shares in millions, except per share amounts)


	Three Months Ended				Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net sales	$	210.3	$	229.1	$	637.9	$	703.8
Cost of sales	136.2		148.7		422.5		464.1
Gross margin	74.1		80.4		215.4		239.7

Selling, general and administrative expenses	45.1		44.2		143.5		150.5
Research and development expenses	8.1		7.8		26.5		25.5
Restructuring and impairment charges	6.3		2.0		7.8		16.4
Other operating (income) expense, net	—		(0.8)		—		(7.5)
Operating income	14.6		27.2		37.6		54.8

Equity income in unconsolidated joint ventures	0.4		0.6		1.2		1.5

Other income (expense), net	(1.5)		0.7		(0.8)		—
Interest expense, net	—		(2.3)		(1.0)		(8.6)
Income before income taxes	13.5		26.2		37.0		47.7
Income tax expense	2.8		7.2		10.4		14.3
Net income	$	10.7	$	19.0	$	26.6	$	33.4

Basic earnings per share	$	0.58	$	1.02	$	1.43	$	1.79
Diluted earnings per share	$	0.58	$	1.02	$	1.43	$	1.79

Shares used in computing:
Basic earnings per share	18.6		18.6		18.6		18.6
Diluted earnings per share	18.6		18.7		18.6		18.7

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROGERS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(Dollars in millions)


	Three Months Ended				Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net income	$	10.7	$	19.0	$	26.6	$	33.4

Foreign currency translation adjustment	25.8		(17.9)		10.9		(3.9)
Pension and other postretirement benefits:

Amortization of loss, net of tax (Note 2)	0.1		0.1		0.3		0.3
Other comprehensive income (loss)	25.9		(17.8)		11.2		(3.6)
Comprehensive income	$	36.6	$	1.2	$	37.8	$	29.8

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROGERS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

(Dollars and shares in millions, except par value)


	September 30, 2024		December 31, 2023
Assets
Current assets
Cash and cash equivalents	$	146.4	$	131.7
Accounts receivable, less allowance for credit losses of $1.5 and $1.1	156.3		161.9
Contract assets	28.1		45.2
Inventories, net	154.4		153.5
Asbestos-related insurance receivables, current portion	4.3		4.3
Other current assets	31.7		30.3
Total current assets	521.2		526.9
Property, plant and equipment, net of accumulated depreciation of $403.7 and $385.7	381.4		366.3
Operating lease right-of-use assets	25.4		18.9
Goodwill	365.7		359.8
Other intangible assets, net of amortization	117.7		123.9
Asbestos-related insurance receivables, non-current portion	52.2		52.2
Investments in unconsolidated joint ventures	9.7		11.1
Deferred income taxes	58.0		49.7
Other long-term assets	8.7		8.4
Total assets	$	1,540.0	$	1,517.2
Liabilities and Shareholders’ Equity
Current liabilities
Accounts payable	$	47.2	$	50.3
Accrued employee benefits and compensation	39.7		31.1
Accrued income taxes payable	6.6		2.0
Operating lease obligations, current portion	4.1		3.5
Asbestos-related liabilities, current portion	5.5		5.5
Other accrued liabilities	19.4		24.0
Total current liabilities	122.5		116.4
Borrowings under revolving credit facility	—		30.0
Operating lease obligations, non-current portion	21.7		15.4
Asbestos-related liabilities, non-current portion	55.1		56.0
Non-current income tax	6.1		7.2
Deferred income taxes	23.8		22.9
Other long-term liabilities	10.1		10.3
Commitments and contingencies (Note 6 and Note 10)
Shareholders’ equity
Capital stock - $1 par value; 50.0 authorized shares; 18.6 and 18.6 shares issued and outstanding	18.6		18.6
Additional paid-in capital	155.7		151.8
Retained earnings	1,181.6		1,155.0
Accumulated other comprehensive loss	(55.2)		(66.4)
Total shareholders' equity	1,300.7		1,259.0
Total liabilities and shareholders' equity	$	1,540.0	$	1,517.2

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROGERS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

(Dollars and shares in millions)


	Three Months Ended				Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Capital Stock
Balance, beginning of period	$	18.6	$	18.6	$	18.6	$	18.6
Shares issued for vested restricted stock units, net of shares withheld for taxes	—		—		0.1		—
Shares issued for employee stock purchase plan	—		—		—		—
Shares issued to directors	—		—		—		—
Shares repurchased	—		—		(0.1)		—
Balance, end of period	18.6		18.6		18.6		18.6
Additional Paid-In Capital
Balance, beginning of period	152.4		145.2		151.8		140.7
Shares issued for vested restricted stock units, net of shares withheld for taxes	(0.1)		(0.1)		(1.4)		(2.6)
Shares issued for employee stock purchase plan	—		—		0.9		—
Shares issued to directors	—		—		—		—
Equity compensation expense	3.4		3.9		12.2		10.9
Shares repurchased	—		—		(7.8)		—
Balance, end of period	155.7		149.0		155.7		149.0
Retained Earnings
Balance, beginning of period	1,170.9		1,112.8		1,155.0		1,098.4
Net income	10.7		19.0		26.6		33.4
Balance, end of period	1,181.6		1,131.8		1,181.6		1,131.8
Accumulated Other Comprehensive Loss
Balance, beginning of period	(81.1)		(71.0)		(66.4)		(85.2)
Other comprehensive income (loss)	25.9		(17.8)		11.2		(3.6)
Balance, end of period	(55.2)		(88.8)		(55.2)		(88.8)
Total Shareholders’ Equity	$	1,300.7	$	1,210.6	$	1,300.7	$	1,210.6

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROGERS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in millions)


	Nine Months Ended
	September 30, 2024		September 30, 2023
Operating Activities:
Net income	$	26.6	$	33.4
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	36.3		39.8
Equity compensation expense	12.2		10.9
Deferred income taxes	(7.4)		(8.3)
Equity in undistributed income of unconsolidated joint ventures	(1.2)		(1.5)
Dividends received from unconsolidated joint ventures	2.5		4.3
Gain on sale of business	—		(0.7)
(Gain) loss on sale or disposal of property, plant and equipment	—		(0.7)

Other non-cash charges, net	0.5		0.1
Changes in assets and liabilities:
Accounts receivable	1.5		(17.5)
Proceeds from insurance related to operations	4.1		5.7
Contract assets	17.0		(8.6)
Inventories, net	(0.3)		22.4
Other current assets	(1.3)		2.1
Accounts payable and other accrued expenses	6.0		(20.2)
Other, net	(3.1)		(1.7)
Net cash provided by operating activities	93.4		59.5

Investing Activities:

Capital expenditures	(40.7)		(34.5)
Disposition of business	—		1.7
Proceeds from the sale of property, plant and equipment, net	—		0.7
Proceeds from insurance claims	—		1.8
Net cash used in investing activities	(40.7)		(30.3)

Financing Activities:

Repayment of debt principal and finance lease obligations	(30.3)		(135.3)
Line of credit issuance costs	—		(1.7)
Payments of taxes related to net share settlement of equity awards	(1.3)		(2.6)
Proceeds from issuance of shares to employee stock purchase plan	0.9		—
Share repurchases	(7.9)		—
Net cash used in financing activities	(38.6)		(139.6)

Effect of exchange rate fluctuations on cash	0.6		1.0

Net increase (decrease) in cash and cash equivalents	14.7		(109.4)
Cash and cash equivalents at beginning of period	131.7		235.9
Cash and cash equivalents at end of period	$	146.4	$	126.5

Supplemental Disclosures:
Accrued capital additions	$	5.3	$	2.5
Cash paid during the year for:
Interest, net of amounts capitalized	$	1.4	$	8.9
Income taxes, net of refunds	$	10.9	$	6.3

The accompanying notes are an integral part of the condensed consolidated financial statements.

ROGERS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Basis of Presentation

As used herein, the terms “Company,” “Rogers,” “we,” “us,” “our” and similar terms mean Rogers Corporation and its consolidated subsidiaries, unless the context indicates otherwise.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, these statements do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, the accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for their fair presentation in accordance with GAAP. All significant intercompany balances and transactions have been eliminated.

Interim results are not necessarily indicative of results for a full year. For further information regarding our accounting policies, refer to the audited consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.

Note 2 – Accumulated Other Comprehensive Loss

The changes in accumulated other comprehensive loss by component were as follows:


(Dollars and accompanying footnotes in millions)	Foreign Currency Translation Adjustments		Pension and Other Postretirement Benefits(1)		Total
Balance as of December 31, 2023	$	(56.8)	$	(9.6)	$	(66.4)
Other comprehensive income (loss) before reclassifications	10.9		—		10.9
Amounts reclassified from accumulated other comprehensive loss	—		0.3		0.3
Net current-period other comprehensive income (loss)	10.9		0.3		11.2
Balance as of September 30, 2024	$	(45.9)	$	(9.3)	$	(55.2)

Balance as of December 31, 2022	$	(75.6)	$	(9.6)	$	(85.2)
Other comprehensive income (loss) before reclassifications	(3.9)		—		(3.9)
Amounts reclassified from accumulated other comprehensive loss	—		0.3		0.3
Net current-period other comprehensive income (loss)	(3.9)		0.3		(3.6)
Balance as of September 30, 2023	$	(79.5)	$	(9.3)	$	(88.8)

(1) Net of taxes of $1.7 million and $1.8 million as of September 30, 2024 and December 31, 2023, respectively. Net of taxes of $1.8 million and $1.9 million as of September 30, 2023 and December 31, 2022, respectively.

Note 3 – Derivatives and Hedging

The valuation of our derivative contracts used to manage their respective risks is described below:

•Foreign Currency – The fair value of any foreign currency option derivative is based upon valuation models applied to current market information such as strike price, spot rate, maturity date and volatility, and by reference to market values resulting from an over-the-counter market or obtaining market data for similar instruments with similar characteristics.

•Commodity – The fair value of copper derivatives is computed using a combination of intrinsic and time value valuation models, which are collectively a function of five primary variables: price of the underlying instrument, time to expiration, strike price, interest rate and volatility. The intrinsic valuation model reflects the difference between the strike price of the underlying copper derivative instrument and the current prevailing copper prices in an over-the-counter market at period end. The time value valuation model incorporates changes in the price of the underlying copper derivative instrument, the time value of money, the underlying copper derivative instrument’s strike price and the remaining time to the underlying copper derivative instrument’s expiration date from the period end date.

As of September 30, 2024, we did not have any derivative contracts that qualified for hedge accounting treatment.

Foreign Currency

During the three months ended September 30, 2024, we entered into U.S. dollar, euro, Korean won, Hungarian forint, and Japanese yen forward contracts. We entered into these foreign currency forward contracts to mitigate certain global transactional exposures. These contracts do not qualify for hedge accounting treatment. As a result, any fair value adjustments required on these contracts are recorded in “Other income (expense), net” in our condensed consolidated statements of operations in the period in which the adjustment occurred.

As of September 30, 2024, the notional values of the remaining foreign currency forward contracts were as follows:


Notional Values of Foreign Currency Derivatives
USD/CNH	$	33,000,189
EUR/USD	€	6,249,973
KRW/USD	₩	3,979,800,000
JPY/EUR	¥	250,000,000
HUF/EUR	Ft	600,000,000

Commodity

As of September 30, 2024, we had 12 outstanding contracts to hedge exposure related to the purchase of copper in our AES operating segment. These contracts are held with financial institutions and are intended to offset rising copper prices and do not qualify for hedge accounting treatment. As a result, any fair value adjustments required on these contracts are recorded in “Other income (expense), net” in our condensed consolidated statements of operations in the period in which the adjustment occurred.

As of September 30, 2024, the volume of our copper contracts outstanding was as follows:


Volume of Copper Derivatives
October 2024 - December 2024			69 metric tons per month
January 2025 - March 2025			69 metric tons per month
April 2025 - June 2025			69 metric tons per month
July 2025 - September 2025			69 metric tons per month

Effects on Financial Statements

The impacts from our derivative instruments on the statements of operations and statements of comprehensive income were as follows:


		Three Months Ended				Nine Months Ended
(Dollars in millions)	Financial Statement Line Item	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Foreign Currency Contracts
Contracts not designated as hedging instruments	Other income (expense), net	$	(0.8)	$	0.3	$	(1.2)	$	1.1
Copper Derivative Contracts
Contracts not designated as hedging instruments	Other income (expense), net	$	(0.1)	$	(0.2)	$	0.3	$	(0.6)

The accounting guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:

•Level 1 – Quoted prices in active markets for identical assets or liabilities.

•Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The fair values of derivative instruments measured at fair value on a recurring basis, categorized by contract type and level of inputs used in the valuation, were as follows:


	Derivative Instruments at Fair Value as of September 30, 2024
(Dollars in millions)	Level 1		Level 2		Level 3		Total(1)
Foreign currency contracts	$	—	$	0.2	$	—	$	0.2
Copper derivative contracts	$	—	$	0.9	$	—	$	0.9


	Derivative Instruments at Fair Value as of December 31, 2023
(Dollars in millions)	Level 1		Level 2		Level 3		Total(1)
Foreign currency contracts	$	—	$	(0.2)	$	—	$	(0.2)
Copper derivative contracts	$	—	$	0.4	$	—	$	0.4

(1) All balances were recorded in the “Other current assets” or “Other accrued liabilities” line items in the condensed consolidated statements of financial position.

Note 4 – Inventories

The “Inventories, net” line item in the condensed consolidated statements of financial position consisted of the following:


(Dollars in millions)	September 30, 2024		December 31, 2023
Raw materials	$	72.0	$	71.5
Work-in-process	44.3		45.6
Finished goods	38.1		36.4
Total inventories	$	154.4	$	153.5

Note 5 - Balance Sheet Items

Restricted Cash

Our restricted cash balance, which was subject to contractual restrictions and not readily available, was recorded in the “Cash and cash equivalents” line item in the condensed consolidated statements of financial position, and served as collateral for letters of credit related to our environmental and workers’ compensation liabilities. This arrangement was terminated in the third quarter of 2024. Our restricted cash balance as of September 30, 2024 and December 31, 2023 was as follows:


(Dollars in millions)	September 30, 2024		December 31, 2023
Restricted Cash	$	—	$	2.2

Accounts Receivable

The “Accounts receivable, less allowance for credit losses” line item in the condensed consolidated statements of financial position consisted of the following:


(Dollars in millions)	September 30, 2024		December 31, 2023
Accounts Receivable - Trade	$	141.3	$	143.2
Accounts Receivable - Other	15.0		18.7
Total	$	156.3	$	161.9

Accounts Payable

The “Accounts payable” line item in the condensed consolidated statements of financial position consisted of the following:


(Dollars in millions)	September 30, 2024		December 31, 2023
Accounts Payable - Trade	$	43.6	$	46.3
Accounts Payable - Other	3.6		4.0
Total	$	47.2	$	50.3

Note 6 - Leases

Finance Leases

Amortization expense related to our finance lease right-of-use assets, which is primarily included in the “Cost of sales” line item of the condensed consolidated statements of operations, was immaterial for each of the three- and nine-month periods ended September 30, 2024 and 2023. Interest expense related to our finance lease obligations, which is included in the “Interest expense, net” line item of the condensed consolidated statements of operations, was immaterial for each of the three- and nine-month periods ended September 30, 2024 and 2023.

Operating Leases

We have operating leases primarily related to manufacturing and R&D facilities as well as vehicles. Our expenses and payments for operating leases were as follows:


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Operating leases expense	$	1.3	$	1.1	$	3.9	$	2.9
Short-term leases expense	$	0.2	$	0.2	$	0.5	$	0.6
Payments on operating lease obligations	$	1.1	$	0.9	$	3.5	$	2.6

Lease Balances in Statements of Financial Position

The assets and liabilities balances related to finance and operating leases reflected in the condensed consolidated statements of financial position were as follows:


(Dollars in millions)	Financial Statement Line Item	September 30, 2024		December 31, 2023
Finance lease right-of-use assets	Property, plant and equipment, net	$	1.4	$	1.5
Operating lease right-of-use assets	Operating lease right-of-use assets	$	25.4	$	18.9

Finance lease obligations, current portion	Other accrued liabilities	$	0.4	$	0.4
Finance lease obligations, non-current portion	Other long-term liabilities	$	1.0	$	1.1
Total finance lease obligations		$	1.4	$	1.5

Operating lease obligations, current portion	Operating lease obligations, current portion	$	4.1	$	3.5
Operating lease obligations, non-current portion	Operating lease obligations, non-current portion	$	21.7	$	15.4
Total operating lease obligations		$	25.8	$	18.9

Net Future Minimum Lease Payments

The following table includes future minimum lease payments under finance and operating leases together with the present value of the net future minimum lease payments as of September 30, 2024:


	Finance						Operating
(Dollars in millions)	Leases Signed		Less: Leases Not Yet Commenced		Leases in Effect		Leases Signed		Less: Leases Not Yet Commenced		Leases in Effect
2024	$	0.1	$	—	$	0.1	$	1.5	$	—	$	1.5
2025	1.6		(1.1)		0.5		5.5		—		5.5
2026	1.7		(1.2)		0.5		4.8		—		4.8
2027	1.5		(1.3)		0.2		3.9		—		3.9
2028	1.4		(1.3)		0.1		3.2		—		3.2
Thereafter	5.2		(5.1)		0.1		13.0		—		13.0
Total lease payments	11.5		(10.0)		1.5		31.9		—		31.9
Less: Interest	(1.8)		1.7		(0.1)		(6.1)		—		(6.1)
Present Value of Net Future Minimum Lease Payments	$	9.7	$	(8.3)	$	1.4	$	25.8	$	—	$	25.8

The following table includes information regarding the lease term and discount rates utilized in the calculation of the present value of net future minimum lease payments:


	September 30, 2024	December 31, 2023
Weighted Average Remaining Lease Term
Finance leases	3.6 years	4.0 years
Operating leases	7.3 years	7.0 years
Weighted Average Discount Rate
Finance leases	4.29%	4.14%
Operating leases	5.56%	5.35%

Note 7 – Goodwill and Other Intangible Assets

Goodwill

The changes in the net carrying amount of goodwill by operating segment were as follows:


(Dollars in millions)	Advanced Electronics Solutions		Elastomeric Material Solutions		Other		Total
December 31, 2023	$	117.7	$	239.9	$	2.2	$	359.8


Foreign currency translation adjustment	0.6		5.3		—		$	5.9
September 30, 2024	$	118.3	$	245.2	$	2.2	$	365.7

Other Intangible Assets

The carrying amount of other intangible assets were as follows:


	September 30, 2024						December 31, 2023
(Dollars in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Customer relationships	$	180.5	$	96.0	$	84.5	$	177.9	$	90.0	$	87.9
Technology	78.1		61.7		16.4		77.4		58.1		19.3
Trademarks and trade names	20.1		7.8		12.3		19.4		7.4		12.0
Covenants not to compete	1.3		1.2		0.1		1.3		0.9		0.4
Total definite-lived other intangible assets	280.0		166.7		113.3		276.0		156.4		119.6
Indefinite-lived other intangible asset	4.4		—		4.4		4.3		—		4.3
Total other intangible assets	$	284.4	$	166.7	$	117.7	$	280.3	$	156.4	$	123.9

In the table above, gross carrying amounts and accumulated amortization may differ from prior periods due to foreign exchange rate fluctuations.

Amortization expense was $3.1 million and $3.3 million for the three months ended September 30, 2024 and 2023, respectively and $9.3 million and $10.0 million for the nine months ended September 30, 2024 and 2023, respectively. The estimated future amortization expense is $3.2 million, $11.1 million, $10.7 million, $10.3 million, and $8.0 million in 2024, 2025, 2026, 2027 and 2028, respectively. These amounts could vary based on changes in foreign currency exchange rates.

The weighted average amortization period as of September 30, 2024, by definite-lived other intangible asset class, is presented in the table below:


						Weighted Average Remaining Amortization Period
Customer relationships						7.1 years
Technology						3.1 years
Trademarks and trade names						9.5 years
Covenants not to compete						0.1 years
Total definite-lived other intangible assets						6.8 years

Note 8 – Pension Benefits and Other Postretirement Benefits

Pension and Other Postretirement Benefit Plans

As of September 30, 2024, we had one qualified noncontributory defined benefit pension plan, the Union Plan, which was frozen and ceased accruing benefits in 2013. Additionally, we sponsor other postretirement benefit plans, including multiple fully insured or self-funded medical plans and life insurance plans for certain retirees. The measurement date for all plans is December 31st for each respective plan year.

Components of Net Periodic Benefit Cost (Credit)

The components of net periodic benefit cost (credit) were as follows:


	Pension Benefits
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(Dollars in millions)	2024		2023		2024		2023

Interest cost	$	0.2	$	0.3	$	0.7	$	0.8
Expected return of plan assets	(0.4)		(0.4)		(1.0)		(1.1)

Amortization of net loss (gain)	0.2		0.1		0.4		0.4

Net periodic benefit cost (credit)	$	—	$	—	$	0.1	$	0.1

Employer Contributions

There were no required or voluntary contributions made to the Union Plan for each of the three- and nine-month periods ended September 30, 2024 and 2023. Additionally, we are not required to make additional contributions to the Union Plan for the remainder of 2024.

As there is no funding requirement for the other postretirement benefit plans, we funded these benefit payments as incurred, which were immaterial for each of the three- and nine-month periods ended September 30, 2024 and 2023, using cash from operations.

Note 9 – Debt

On March 24, 2023, we entered into a Fifth Amended Credit Agreement with each of the lenders party thereto, JPMorgan Chase Bank, N.A. as administrative agent, and HSBC Bank USA, National Association, Wells Fargo Bank, National Association, Citibank, N.A. and Citizens Bank, N.A. as Co-Syndication Agents. The Fifth Amended Credit Agreement amends and restates the Fourth Amended Credit Agreement, and provides for (1) a revolving credit facility with up to $450.0 million of revolving loans, with sub-limits for multicurrency borrowings, letters of credit and swing-line notes, and (2) a $225.0 million expansion feature. Borrowings may be used to finance working capital needs, for letters of credit and for general corporate purposes in the ordinary course of business, including the financing of permitted acquisitions (as defined in the Fifth Amended Credit Agreement). The Fifth Amended Credit Agreement extends the maturity, the date on which all amounts borrowed or outstanding under the Fifth Amended Credit Agreement are due, from March 31, 2024 to March 24, 2028.

All obligations under the Fifth Amended Credit Agreement are guaranteed by each of our existing and future material domestic subsidiaries, as defined in the Fifth Amended Credit Agreement (the Guarantors). The obligations are also secured by a Fifth Amended and Restated Pledge and Security Agreement, dated as of March 24, 2023, entered into by us and the Guarantors which grants to the administrative agent, for the benefit of the lenders, a security interest, subject to certain exceptions, in substantially all of the non-real estate assets of ours and the Guarantors. These assets include, but are not limited to, receivables, equipment, intellectual property, inventory, and stock in certain subsidiaries.

Borrowings under the Fifth Amended Credit Agreement bear interest based on one of two options. Alternate base rate loans will bear interest at a rate that includes a base reference rate plus a spread of 62.5 to 100.0 basis points, depending on our leverage ratio. The base reference rate will be the greater of the (1) prime rate, (2) federal funds effective rate plus 50 basis points, and (3) one-month Term SOFR plus 110 basis points. Loans bearing an interest rate determined by reference to the Adjusted Term SOFR Rate, the Adjusted EURIBOR, or the Adjusted TIBOR (each as defined in the Fifth Amended Credit Agreement) will bear interest based on the screen rate plus a spread of 162.5 to 200.0 basis points, depending on our leverage ratio. Based on our leverage ratio as of September 30, 2024, the spread was 162.5 basis points.

In addition to interest payable on the principal amount of indebtedness outstanding, we incur an annual fee of 25 to 35 basis points (based upon our leverage ratio), paid quarterly, of the unused amount of the lenders’ commitments under the Fifth Amended Credit Agreement.

The Fifth Amended Credit Agreement contains customary representations and warranties, covenants, mandatory prepayments and events of default under which the Company’s payment obligations may be accelerated. The financial covenants include a requirement to maintain (1) a total net leverage ratio of no more than 3.25 to 1.00, subject to a one-time election to increase the maximum total net leverage ratio to 3.75 to 1.00 for one fiscal year in connection with a permitted acquisition, and (2) an interest coverage ratio of no less than 3.00 to 1.00. We are permitted to net up to $50.0 million of unrestricted domestic cash and cash equivalents in the calculation of the total net leverage ratio. The Fifth Amended Credit Agreement generally permits us to pay cash dividends to our shareholders, provided that (i) no default or event of default has occurred and is continuing or would result from the dividend payment and (ii) our total net leverage ratio does not exceed 2.75 to 1.00. If our total net leverage ratio exceeds 2.75 to 1.00, we may nonetheless make up to $20.0 million in restricted payments, including cash dividends, during the fiscal year, provided that no default or event of default has occurred and is continuing or would result from the payments. Our total net leverage ratio did not exceed 2.75 to 1.00 and our interest coverage ratio was greater than or equal to 3.00 to 1.00 as of September 30, 2024.

There were no borrowings under the Fifth Amended Credit Agreement during the three and nine months ended September 30, 2024 or the three and nine months ended September 30, 2023. We are not required to make any quarterly principal payments under the Fifth Amended Credit Agreement. We made no payments and a $30.0 million discretionary principal payment during the three and nine months ended September 30, 2024, respectively. We made $50.0 million and $135.0 million of discretionary principal payments during the three and nine months ended September 30, 2023, respectively.

We had no outstanding borrowings under our revolving credit facility as of September 30, 2024, and $30.0 million as of December 31, 2023. We had $1.7 million and $2.1 million of outstanding line of credit issuance costs as of September 30, 2024 and December 31, 2023, respectively, which will be amortized over the life of the Fifth Amended Credit Agreement.

Note 10 – Commitments and Contingencies

We are currently engaged in the following material environmental and legal proceedings:

Asbestos

Overview

We, like many other industrial companies, have been named as a defendant in a number of lawsuits filed in courts across the country by persons alleging personal injury from exposure to products containing asbestos. We have never mined, milled, manufactured or marketed asbestos; rather, we made and provided to industrial users a limited number of products that contained encapsulated asbestos, but we stopped manufacturing these products in the late 1980s. Most of the claims filed against us involve numerous defendants, sometimes as many as several hundred. In virtually all of the cases against us, the plaintiffs are seeking unspecified damages above a jurisdictional minimum against multiple defendants who may have manufactured, sold or used asbestos-containing products to which the plaintiffs were allegedly exposed and from which they purportedly suffered injury. Most of these cases are being litigated in Maryland, Illinois, Missouri and New York; however, we are also defending cases in other states. We continue to vigorously defend these cases, primarily on the basis of the plaintiffs’ inability to establish compensable loss as a result of exposure to our products. The indemnity and defense costs of our asbestos-related product liability litigation to date have been substantially covered by insurance.

The following table summarizes the change in number of asbestos claims outstanding for the nine months ended September 30, 2024:


			Asbestos Claims
Claims outstanding as of January 1, 2024			506
New claims filed			112
Pending claims concluded(1)			(102)
Claims outstanding as of September 30, 2024			516

(1) For the nine months ended September 30, 2024, 78 claims were dismissed and 24 claims were settled. Settlements totaled approximately $11.4 million for the nine months ended September 30, 2024.

Impact on Financial Statements

We recognize a liability for asbestos-related contingencies that are probable of occurrence and reasonably estimable. In connection with the recognition of liabilities for asbestos-related matters, we record asbestos-related insurance receivables that are deemed probable.

The liability projection period covers all current and future indemnity and defense costs through 2064, which represents the expected end of our asbestos liability exposure with no further ongoing claims expected beyond that date. This conclusion was based on our history and experience with the claims data, the diminished volatility and consistency of observable claims data,

the period of time that has elapsed since we stopped manufacturing products that contained encapsulated asbestos and an expected downward trend in claims due to the average age of our claimants, which is approaching the average life expectancy.

To date, the indemnity and defense costs of our asbestos-related product liability litigation have been substantially covered by insurance. Although we have exhausted coverage under some of our insurance policies, we believe that we have applicable primary, excess and/or umbrella coverage for claims arising with respect to most of the years during which we manufactured and marketed asbestos-containing products. In addition, we have entered into a cost sharing agreement with most of our primary, excess and umbrella insurance carriers to facilitate the ongoing administration and payment of claims covered by the carriers. The cost sharing agreement may be terminated by any party, but will continue until a party elects to terminate it. As of the filing date for this report, the agreement has not been terminated, and no carrier had informed us that it intends to terminate the agreement. We expect to continue to exhaust individual primary, excess and umbrella coverages over time, and there is no assurance that such exhaustion will not accelerate due to additional claims, damages and settlements or that coverage will be available as expected. We are responsible for uninsured indemnity and defense costs, and we incurred an immaterial amount of expenses for each of the three- and nine-month periods ended September 30, 2024 and 2023, respectively, related to such costs.

The amounts recorded for the asbestos-related liability and the related insurance receivables are based on facts known at the time and a number of assumptions. However, projecting for future events, such as the number of new claims to be filed each year, the average cost of disposing of such claims, the length of time it takes to dispose of such claims, coverage issues among insurers and the continuing solvency of various insurance companies, as well as the numerous uncertainties surrounding asbestos litigation in the United States, could cause the actual liability and insurance recoveries for us to be higher or lower than those projected or recorded. The full extent of our financial exposure to asbestos-related litigation remains very difficult to estimate and could include both compensatory and punitive damage awards.

Changes recorded in the estimated liability and estimated insurance recovery based on projections of asbestos litigation and corresponding insurance coverage, result in the recognition of expense or income.

Our projected asbestos-related liabilities and insurance receivables were as follows:


(Dollars in millions)	September 30, 2024		December 31, 2023
Asbestos-related liabilities	$	60.6	$	61.5
Asbestos-related insurance receivables	$	56.5	$	56.5

Environmental Voluntary Corrective Action Program

Our location in Rogers, Connecticut is part of the Connecticut Voluntary Corrective Action Program (VCAP). As part of this program, we partnered with the Connecticut Department of Energy and Environmental Protection (CT DEEP) to determine the corrective actions to be taken at the site related to contamination issues. We evaluated this matter and completed internal due diligence work related to the site in the fourth quarter of 2015. Remediation activities on the site are ongoing and are recorded as reductions to the accrual as they are incurred. We have incurred $0.7 million of aggregate remediation costs through September 30, 2024, and the accrual for future remediation efforts is $2.0 million.

Other Matters

In addition to the above issues, the nature and scope of our business brings us in regular contact with the general public and a variety of businesses and government agencies. Such activities inherently subject us to the possibility of litigation, including environmental and product liability matters that are defended and handled in the ordinary course of business. We have established accruals for matters for which management considers a loss to be probable and reasonably estimable. It is the opinion of management that facts known at the present time do not indicate that such litigation will have a material adverse impact on our results of operations, financial position or cash flows.

Note 11 – Earnings Per Share

Basic earnings per share is based on the weighted average number of common shares outstanding. Diluted earnings per share is based on the weighted average number of common shares outstanding and all dilutive potential common shares outstanding.

The following table sets forth the computation of basic and diluted earnings per share:


(Dollars and shares in millions, except per share amounts)	Three Months Ended				Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Numerator:
Net income	$	10.7	$	19.0	$	26.6	$	33.4
Denominator:
Weighted-average shares outstanding - basic	18.6		18.6		18.6		18.6
Effect of dilutive shares	—		0.1		—		0.1
Weighted-average shares outstanding - diluted	18.6		18.7		18.6		18.7
Basic earnings per share	$	0.58	$	1.02	$	1.43	$	1.79
Diluted earnings per share	$	0.58	$	1.02	$	1.43	$	1.79

Dilutive shares are calculated using the treasury stock method and primarily include unvested restricted stock units. Anti-dilutive shares are excluded from the calculation of diluted shares and diluted earnings per share. For the three months ended September 30, 2024 and 2023, an immaterial number of shares were excluded.

Note 12 – Capital Stock and Equity Compensation

Share Repurchases

In 2015, we initiated a share repurchase program (the Program) of up to $100.0 million of the Company’s capital stock to mitigate the dilutive effects of stock option exercises and vesting of restricted stock units granted by the Company, in addition to enhancing shareholder value. In 2024, the Board of Directors authorized an additional $100.0 million to be used for share repurchases. The Program has no expiration date and may be suspended or discontinued at any time without notice. For the three and nine months ended September 30, 2024, we purchased no shares and 72,393 shares, respectively, for a total value of $0.0 million and $7.8 million, respectively, using cash from operations and cash on hand. As of September 30, 2024, $116.2 million remained available to purchase under the Program. Our stock repurchases may occur from time to time through open market purchases, privately negotiated transactions or plans designed to comply with Rule 10b5-1 promulgated under the Exchange Act.


(Dollars in millions, except shares and per share amounts)
Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet be Purchased under the Plans or Programs
March 1, 2024 to March 31, 2024	1,500	$	109.92	1,500	$	23.8
April 1, 2024 to April 31, 2024	70,893	$	108.79	70,893	$	116.2

Equity Compensation

Performance-Based Restricted Stock Units

As of September 30, 2024, we had outstanding performance-based restricted stock units with a market condition from 2024 and 2023. These awards generally cliff vest at the end of a three-year measurement period. However, employees whose employment terminates during the measurement period due to death, disability, or, in certain cases, retirement may receive a pro-rata payout based on the number of days they were employed during the measurement period. Participants are eligible to be awarded shares ranging from 0% to 200% of the original award amount, based on certain defined performance measures.

The performance-based restricted stock units with a market condition have one measurement criterion: the three-year total shareholder return (“TSR”) on our capital stock as compared to that of a specified group of peer companies. The fair value of this measurement criterion was determined on the grant date using a Monte Carlo simulation valuation model. We recognize compensation expense on all of these awards on a straight-line basis over the vesting period with no changes for final projected payout of the awards. We account for forfeitures as they occur.

The following table sets forth the assumptions used in the Monte Carlo calculation for each material award granted in 2024 and 2023:


	February 19, 2024	February 13, 2024	February 9, 2023
Expected volatility	46.3%	46.2%	53.2%
Expected term (in years)	2.9	2.9	2.9
Risk-free interest rate	4.35%	4.35%	4.08%

Expected volatility – In determining expected volatility, we have considered a number of factors, including historical volatility.

Expected term – We use the vesting period of the award to determine the expected term assumption for the Monte Carlo simulation valuation model.

Risk-free interest rate – We use an implied “spot rate” yield on U.S. Treasury Constant Maturity rates as of the grant date for our assumption of the risk-free interest rate.

Expected dividend yield – We do not currently pay dividends on our capital stock; therefore, a dividend yield of 0% was used in the Monte Carlo simulation valuation model.

As of September 30, 2024, we had outstanding performance-based restricted stock units with a performance condition from 2024. These awards generally cliff vest at the end of a two-year performance period. However, employees whose employment terminates during the measurement period due to death, disability, or, in certain cases, retirement may receive a pro-rata payout based on the number of days they were employed during the measurement period. Participants are eligible to be awarded shares ranging from 0% to 200% of the original award amount, based on certain defined performance measures.

The performance-based restricted stock units with a performance condition have one measurement criterion: 2025 net revenue. The fair value of these awards was determined based on the market value of the underlying stock price at the grant date with cumulative compensation expense recognized to-date being increased or decreased based on the changes in the forecasted payout percentage as of the end of each reporting period. We account for forfeitures as they occur.

A summary of activity of the outstanding performance-based restricted stock units for the nine months ended September 30, 2024 is presented below:


			Performance-Based Restricted Stock Units
Awards outstanding as of December 31, 2023			73,528
Awards granted			79,700
Stock issued			—
Awards cancelled			(40,862)
Awards outstanding as of September 30, 2024			112,366

We recognized $1.4 million of compensation expense for performance-based restricted stock units for each of the three month periods ended September 30, 2024 and 2023. We recognized $4.7 million and $2.6 million of compensation expense for performance-based restricted stock units for the nine months ended September 30, 2024 and 2023, respectively.

Time-Based Restricted Stock Units

As of September 30, 2024, we had time-based restricted stock unit awards from 2024, 2023, 2022 and 2021 outstanding. The outstanding awards all ratably vest on the first, second and third anniversaries of the original grant date. However, employees whose employment terminates during the measurement period due to death, disability, or, in certain cases, retirement may receive a pro-rata payout based on the number of days they were employed subsequent to the last grant anniversary date. Each time-based restricted stock unit represents a right to receive one share of Rogers’ capital stock at the end of the vesting period. The fair value of the award is determined by the market value of the underlying stock price at the grant date. We recognize compensation expense on all of these awards on a straight-line basis over the vesting period. We account for forfeitures as they occur.

A summary of activity of the outstanding time-based restricted stock units for the nine months ended September 30, 2024 is presented below:


			Time-Based Restricted Stock Units
Awards outstanding as of December 31, 2023			100,999
Awards granted			68,060
Stock issued			(37,874)
Awards cancelled			(20,123)
Awards outstanding as of September 30, 2024			111,062

We recognized $1.9 million and $2.5 million of compensation expense for time-based restricted stock units for the three months ended September 30, 2024 and 2023, respectively. We recognized $5.9 million and $7.1 million of compensation expense for time-based restricted stock units for the nine months ended September 30, 2024 and 2023, respectively.

Deferred Stock Units

We grant deferred stock units to non-management directors. These awards are fully vested on the date of grant and the related shares are generally issued on the 13-month anniversary of the grant date unless the individual elects to defer the receipt of those shares. Each deferred stock unit results in the issuance of one share of Rogers’ capital stock. The grant of deferred stock units is typically done annually during the second quarter of each year. The fair value of the award is determined by the market value of the underlying stock price at the grant date.

A summary of activity of the outstanding deferred stock units for the nine months ended September 30, 2024 is presented below:


			Deferred Stock Units
Awards outstanding as of December 31, 2023			8,100
Awards granted			10,950
Stock issued			(7,150)
Awards outstanding as of September 30, 2024			11,900

We recognized no compensation expense for deferred stock units for the three months ended September 30, 2024, and 2023, respectively. We recognized $1.3 million and $1.2 million of compensation expense for the nine months ended September 30, 2024 and 2023, respectively.

Employee Stock Purchase Plan

We have an ESPP that allows eligible employees to purchase, through payroll deductions, shares of our capital stock at a discount to fair market value. The ESPP has two six-month offering periods each year, the first beginning in mid-December and ending in mid-June and the second beginning in mid-June and ending in mid-December. The ESPP contains a look-back feature that allows the employee to acquire shares of our capital stock at a 15% discount from the underlying market price at the beginning or end of the applicable period, whichever is lower. We recognize compensation expense on this plan ratably over the offering period based on the fair value of the anticipated number of shares that will be issued at the end of each offering period. Compensation expense is adjusted at the end of each offering period for the actual number of shares issued. Fair value is determined based on two factors: (i) the 15% discount on the underlying stock’s market value on the first day of the applicable offering period, and (ii) the fair value of the look-back feature determined by using the Black-Scholes model. We recognized $0.1 million and $0.4 million of expense associated with the ESPP for the three and nine months ended September 30, 2024, respectively.

Note 13 – Operating Segment Information

Our reporting structure is comprised of the following strategic operating segments: AES and EMS. The remaining operations, which represent our non-core businesses, are reported in the Other operating segment.

Our AES operating segment designs, develops, manufactures and sells circuit materials, ceramic substrate materials, busbars and cooling solutions for applications in EV/HEV, automotive (e.g., ADAS), aerospace and defense (e.g., antenna systems, communication systems and phased array radar systems), renewable energy (e.g., wind and solar), wireless infrastructure (e.g., power amplifiers, antennas and small cells), mass transit, industrial (e.g., variable frequency drives), connected devices (e.g., mobile internet devices and thermal solutions) and wired infrastructure (e.g., computing and internet protocol infrastructure) markets.

Our EMS operating segment designs, develops, manufactures and sells engineered material solutions for a wide variety of applications and markets. These include polyurethane and silicone materials used in cushioning, gasketing and sealing, and vibration management applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, aerospace and defense, footwear and impact mitigation markets; customized silicones used in flex heater and semiconductor thermal applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, aerospace and defense and medical markets; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications for EV/HEV, general industrial, automotive and aerospace and defense markets.

Our Other operating segment consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.

The following table presents a disaggregation of revenue from contracts with customers and other pertinent financial information, for the periods indicated; inter-segment sales have been eliminated from the net sales data:


(Dollars in millions)	Advanced Electronics Solutions		Elastomeric Material Solutions		Other		Total
Three Months Ended September 30, 2024
Net sales - recognized over time	$	37.8	$	1.0	$	3.8	$	42.6
Net sales - recognized at a point in time	74.4		93.2		0.1		167.7
Total net sales	$	112.2	$	94.2	$	3.9	$	210.3
Operating income	$	0.3	$	13.2	$	1.1	$	14.6

Three Months Ended September 30, 2023
Net sales - recognized over time	$	60.7	$	1.3	$	4.1	$	66.1
Net sales - recognized at a point in time	65.6		96.7		0.7		163.0
Total net sales	$	126.3	$	98.0	$	4.8	$	229.1
Operating income	$	5.7	$	19.9	$	1.6	$	27.2

Nine Months Ended September 30, 2024
Net sales - recognized over time	$	130.2	$	4.3	$	13.1	$	147.6
Net sales - recognized at a point in time	219.6		270.3		0.4		490.3
Total net sales	$	349.8	$	274.6	$	13.5	$	637.9
Operating income	$	7.7	$	25.7	$	4.2	$	37.6

Nine Months Ended September 30, 2023
Net sales - recognized over time	$	180.3	$	17.4	$	12.0	$	209.7
Net sales - recognized at a point in time	212.1		278.2		3.8		494.1
Total net sales	$	392.4	$	295.6	$	15.8	$	703.8
Operating income	$	6.0	$	43.3	$	5.5	$	54.8

Net sales by operating segment and by geographic area were as follows:


(Dollars in millions)	Net Sales(1)
Region/Country	Advanced Electronics Solutions		Elastomeric Material Solutions		Other		Total
Three Months Ended September 30, 2024
United States	$	19.2	$	32.8	$	0.9	$	52.9
Other Americas	0.3		4.1		—		4.4
Total Americas	19.5		36.9		0.9		57.3
China	32.0		29.9		1.0		62.9
Other APAC	27.8		8.3		0.5		36.6
Total APAC	59.8		38.2		1.5		99.5
Germany	18.2		6.5		0.1		24.8
Other EMEA	14.7		12.6		1.4		28.7
Total EMEA	32.9		19.1		1.5		53.5
Total net sales	$	112.2	$	94.2	$	3.9	$	210.3
Three Months Ended September 30, 2023
United States	$	20.4	$	37.3	$	1.0	$	58.7
Other Americas	0.3		2.5		—		2.8
Total Americas	20.7		39.8		1.0		61.5
China	33.7		28.3		1.8		63.8
Other APAC	20.7		8.8		0.5		30.0
Total APAC	54.4		37.1		2.3		93.8
Germany	24.8		6.2		0.1		31.1
Other EMEA	26.4		14.9		1.4		42.7
Total EMEA	51.2		21.1		1.5		73.8
Total net sales	$	126.3	$	98.0	$	4.8	$	229.1

(1)Net sales are allocated to countries based on the location of the customer. The table above lists individual countries with 10% or more of net sales for the periods indicated.


(Dollars in millions)	Net Sales(1)
Region/Country	Advanced Electronics Solutions		Elastomeric Material Solutions		Other		Total
Nine Months Ended September 30, 2024
United States	$	57.4	$	103.3	$	2.9	$	163.6
Other Americas	3.6		11.5		0.3		15.4
Total Americas	61.0		114.8		3.2		179.0
China	105.3		75.7		3.6		184.6
Other APAC	78.4		23.0		2.1		103.5
Total APAC	183.7		98.7		5.7		288.1
Germany	56.8		21.3		0.4		78.5
Other EMEA	48.3		39.8		4.2		92.3
Total EMEA	105.1		61.1		4.6		170.8
Total net sales	$	349.8	$	274.6	$	13.5	$	637.9
Nine Months Ended September 30, 2023
United States	$	63.3	$	123.1	$	3.1	$	189.5
Other Americas	3.2		12.0		0.3		15.5
Total Americas	66.5		135.1		3.4		205.0
China	110.2		69.2		6.2		185.6
Other APAC	67.8		23.8		1.9		93.5
Total APAC	178.0		93.0		8.1		279.1
Germany	74.0		22.4		0.3		96.7
Other EMEA	73.9		45.1		4.0		123.0
Total EMEA	147.9		67.5		4.3		219.7
Total net sales	$	392.4	$	295.6	$	15.8	$	703.8

(1)Net sales are allocated to countries based on the location of the customer. The table above lists individual countries with 10% or more of net sales for the periods indicated.

We have contract assets primarily related to unbilled revenue for revenue recognized related to products that are deemed to have no alternative use whereby we have the right to payment. Revenue is recognized in advance of billing to the customer in these circumstances as billing is typically performed at the time of shipment to the customer. The unbilled revenue is included in contract assets on the condensed consolidated statements of financial position.

Contract assets by operating segment were as follows:


(Dollars in millions)	September 30, 2024		December 31, 2023
Advanced Electronics Solutions	$	23.7	$	41.4
Elastomeric Material Solutions	0.2		0.4
Other	4.2		3.4
Total contract assets	$	28.1	$	45.2

We did not have any contract liabilities as of September 30, 2024 or December 31, 2023. No impairment losses were recognized for each of the three- and nine-month periods ended September 30, 2024 and 2023, respectively, on any receivables or contract assets arising from our contracts with customers.

Note 14 – Supplemental Financial Information

Restructuring and Impairment Charges

The components of the “Restructuring and impairment charges” line item in the condensed consolidated statements of operations were as follows:


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Restructuring charges
Global workforce reduction	$	—	$	0.7	$	—	$	8.8
Facility consolidations	—		1.3		0.2		7.6
Manufacturing footprint consolidation	5.9		—		6.3		—
R&D facility exit	0.4		—		1.3		—
Total restructuring charges	$	6.3	$	2.0	$	7.8	$	16.4




Total restructuring and impairment charges	$	6.3	$	2.0	$	7.8	$	16.4

Restructuring Charges - Global Workforce Reduction

On February 16, 2023, we announced a plan to reduce our global workforce that was substantially completed in the first half of 2023, and concluded in the fourth quarter of 2023. The plan significantly reduced our manufacturing costs and operating expenses. We incurred $8.8 million in pre-tax restructuring charges related to this plan, of which $0.7 million and $8.8 million was incurred in the three and nine months ended September 30, 2023, respectively, and substantially all of which was in the form of cash-based expenditures, employee severance and other termination benefits.

Restructuring Charges - Facility Consolidations

In late 2022 and early 2023, we announced our intention to exit certain facilities in the U.S. and Asia. The plan significantly reduced our manufacturing costs and operating expenses. We have incurred $8.3 million in pre-tax restructuring charges to-date related to these facility consolidations, of which an immaterial amount and $0.2 million was incurred in the three and nine months ended September 30, 2024, respectively, and $1.3 million and $7.6 million was incurred in the three and nine months ended September 30, 2023, respectively, the majority of which were in the form of accelerated depreciation.

As part of our facility consolidations plan, in February 2023, we entered into an asset purchase agreement to sell our high-performance engineered cellular elastomer business in our EMS operating segment for a purchase price of $1.8 million. The first phase of the deal, which pertained to the net assets other than the land and building, was completed in late March 2023, while the second phase, which pertained to the sale of the land and building, was completed in early September 2023. Of the $1.8 million purchase price, $1.0 million and $0.8 million were allocated to the first and second phases of the deal, respectively. The first phase of the deal included $3.7 million in assets and $3.1 million in liabilities. The assets were primarily comprised of accounts receivable, contract assets and inventories, while the liabilities were primarily comprised of accounts payable and other accrued liabilities, along with the previously recognized accrual against the net assets of the business based on the estimated fair value of the business in December 2022. We incurred $1.2 million of selling costs in 2023, which were recorded in “Selling, general and administrative expenses” in our condensed consolidated statements of operations.

As of September 30, 2024, and as of December 31, 2023, we included $13.1 million of assets held for sale within the “Other current assets” financial statement line item of our condensed consolidated statements of financial position, representing the land and building at our Price Road facility in Chandler, Arizona. We expect the sale of this facility to be completed in late 2024 or early 2025. In September 2023, we entered into an agreement to sell one of our Suzhou, China facilities, which had a carrying value of $3.0 million, for $6.8 million resulting in a pre-tax gain of $1.9 million, inclusive of selling and disposal costs. The sale was completed in December 2023. The net impact of this transaction was recorded in the “Other operating (income) expense, net” line item in the condensed consolidated statements of operations.

Restructuring Charges - Manufacturing Footprint Consolidation

On June 6, 2024, we announced our intent to consolidate our high frequency circuit material manufacturing operations, impacting our Evergem, Belgium facility. We anticipate the plan to be completed in the second half of 2025. The plan is expected to significantly reduce our manufacturing costs and operating expenses. We estimate this will improve operating income between $7.0 million and $9.0 million annually. We expect to incur approximately $22.0 million to $28.0 million in pre-tax restructuring charges related to this plan, the majority of which are expected to be in the form of cash-based expenditures related to employee severance and other termination benefits. Most of the non-cash expenditures will be in the form of accelerated depreciation.

We incurred $5.9 million of restructuring charges related to this plan in the three months ended September 30, 2024, of which $4.7 million relates to severance and other termination benefits and $1.2 million in the form of accelerated depreciation. We incurred $6.3 million of restructuring charges related to this plan in the nine months ended September 30, 2024, of which $4.7 million relates to severance and other termination benefits and $1.6 million in the form of accelerated depreciation.

Severance and related benefits activity related to the manufacturing footprint consolidation plan is presented in the table below for the nine months ended September 30, 2024:


(Dollars in thousands)	Manufacturing Footprint Consolidation Restructuring Severance and Related Benefits
Balance as of December 31, 2023	$	—
Provisions	4.7
Payments	—
Foreign currency translation adjustment	0.1
Balance as of September 30, 2024	$	4.8

Restructuring Charges - R&D Facility Exit

On June 13, 2024, we announced that we will close our Burlington, Massachusetts Innovation Center facility by the end of 2024. We expect to incur approximately $1.3 million to $1.7 million in pre-tax restructuring charges related to this plan, almost all of which are expected to be in the form of cash-based expenditures related to employee severance and other termination benefits or non-cash expenditures in the form of accelerated depreciation and amortization.

We incurred $0.4 million in pre-tax restructuring charges in the three months ended September 30, 2024, respectively, of which $0.3 million relates to severance and other termination benefits. We incurred $1.3 million in pre-tax restructuring charges in the nine months ended September 30, 2024, of which $0.6 million relates to severance and other termination benefits and $0.7 million in the form of accelerated depreciation.

Allocation of Restructuring and Impairment Charges to Operating Segments

The following table summarizes the allocation of restructuring and impairment charges to our operating segments:


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Advanced Electronics Solutions
Allocated restructuring charges	$	6.1	$	1.6	$	7.2	$	10.2

Elastomeric Material Solutions
Allocated restructuring charges	0.2		0.4		0.6		6.2

Total restructuring and impairment charges	$	6.3	$	2.0	$	7.8	$	16.4

Other Operating (Income) Expense, Net

The components of “Other operating (income) expense, net” line item in the condensed consolidated statements of operations, were as follows:


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
UTIS fire
Professional services	$	—	$	0.1	$	—	$	0.6
Insurance recoveries	—		(0.7)		—		(7.4)
Total UTIS fire	—		(0.6)		—		(6.8)
(Gain) loss on sale or disposal of property, plant and equipment	—		(0.2)		—		(0.7)

Total other operating (income) expense, net	$	—	$	(0.8)	$	—	$	(7.5)

In early February 2021, there was a fire at our UTIS manufacturing facility in Ansan, South Korea, which manufactures eSorba® polyurethane foams used in portable electronics and display applications. The site was safely evacuated and there were no reported injuries; however, there was extensive damage to the manufacturing site and some damage to nearby property. Commercial production at our new location in Siheung, South Korea commenced in late January 2023.

In connection with the UTIS fire, we recognized insurance recoveries of $0.7 million and $7.4 million related to our ongoing insurance claims for business interruption and property damage for the three and nine months ended September 30, 2023, respectively. We incurred $0.1 million and $0.6 million for various professional services for the three and nine months ended September 30, 2023, respectively, in connection with the pursuit of our insurance claims.

Interest Expense, Net

The components of “Interest expense, net” line item in the condensed consolidated statements of operations, were as follows:


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Interest on revolving credit facility	$	—	$	(1.9)	$	(0.5)	$	(8.3)
Line of credit fees	(0.2)		(0.3)		(0.8)		(0.6)
Debt issuance amortization costs	(0.2)		(0.1)		(0.4)		(0.5)
Interest income	0.5		0.2		0.8		1.0
Other	(0.1)		(0.2)		(0.1)		(0.2)
Total interest expense, net	$	—	$	(2.3)	$	(1.0)	$	(8.6)

Note 15 – Income Taxes

The below discussion of the effective tax rate for the periods presented in the consolidated statements of operations is in comparison to the 21% U.S. statutory federal income tax rate.

Our effective tax rate was 20.7% in the third quarter of 2024. During the third quarter of 2024, our effective tax rate was favorably impacted by a decrease of reserves for uncertain tax positions, partially offset by the mix of income in higher tax rate jurisdictions.

During the third quarter of 2023, our effective tax rate was 27.3%. During the third quarter of 2023, our effective tax rate was unfavorably impacted primarily by the mix of income in higher tax rate jurisdictions.

For the first nine months of 2024, the Company’s effective tax rate on its income before taxes was 28.1%. The effective tax rate for the first nine months of 2024 was unfavorably impacted primarily by (i) the write-off of deferred tax assets related to stock compensation and, (ii) the mix of income in higher tax rate jurisdictions, partially offset by (iii) a decrease of reserves for uncertain tax positions.

During the first nine months of 2023, the Company’s effective tax rate on its income before taxes was 30.0%. The effective tax rate for the first nine months of 2023 was unfavorably impacted by (i) the increase in the valuation allowance attributable to loss jurisdictions in which no benefit is anticipated to be realized and (ii) the mix of income in higher tax rate jurisdictions.

The OECD Pillar 2 guidelines published to date include transition and safe harbor rules around the implementation of the Pillar 2 global minimum tax of 15%. Based on current enacted legislation effective in 2024 and our structure, we do not expect a

material impact in 2024. We are monitoring developments and evaluating the impacts these new rules will have on our future effective income tax rate, tax payments, financial condition, and results of operations.

Note 16 - Recent Accounting Standards

Recently Issued Standards

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 enhances segment reporting under Topic 280 by expanding the breadth and frequency of segment disclosures. This amendment will improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Adoption of the standard requires using the retrospective approach. We will adopt ASU 2023-07 in our 2024 10-K using a retrospective transition method.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. Adoption of the standard should be applied on a prospective basis and retrospective application to all periods presented is permitted. We will adopt ASU 2023-09 in our 2025 10-K using a prospective transition method.

Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Position

As used herein, the “Company,” “Rogers,” “we,” “us,” “our” and similar terms include Rogers Corporation and its subsidiaries, unless the context indicates otherwise.

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Such statements are generally accompanied by words such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “foresee,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “seek,” “target” or similar expressions that convey uncertainty as to future events or outcomes. Forward-looking statements are based on assumptions and beliefs that we believe to be reasonable; however, assumed facts almost always vary from actual results, and the differences between assumed facts and actual results could be material depending upon the circumstances. Where we express an expectation or belief as to future results, that expectation or belief is expressed in good faith and based on assumptions believed to have a reasonable basis. We cannot assure you, however, that the stated expectation or belief will occur or be achieved or accomplished. Among the factors that could cause our results to differ materially from those indicated by forward-looking statements are risks and uncertainties inherent in our business including, without limitation:

•failure to capitalize on, volatility within, or other adverse changes with respect to our growth drivers, such as delays in adoption or implementation of new technologies;

•failure to successfully execute on our long-term growth strategy as a standalone company;

•uncertain business, economic and political conditions in the U.S. and abroad, particularly in China, Germany, Belgium, England, South Korea and Hungary where we maintain significant manufacturing, sales or administrative operations;

•the trade policy dynamics between the U.S. and China reflected in trade agreement negotiations, the imposition of tariffs and other trade restrictions, as well as the potential for U.S.-China supply chain decoupling;

•fluctuations in foreign currency exchange rates;

•our ability to develop innovative products and the extent to which they are incorporated into end-user products and systems;

•the extent to which end-user products and systems incorporating our products achieve commercial success;

•the ability and willingness of our sole or limited source suppliers to deliver certain key raw materials, including commodities, to us in a timely and cost-effective manner;

•intense global competition affecting both our existing products and products currently under development;

•business interruptions due to catastrophes or other similar events, such as natural disasters, war, terrorism or public health crises;

•the impact of sanctions, export controls and other foreign asset or investment restriction;

•failure to realize, or delays in the realization of, anticipated benefits of acquisitions and divestitures due to, among other things, the existence of unknown liabilities or difficulty integrating acquired businesses;

•our ability to attract and retain management and skilled technical personnel;

•our ability to protect our proprietary technology from infringement by third parties and/or allegations that our technology infringes third party rights;

•changes in effective tax rates or tax laws and regulations in the jurisdictions in which we operate;

•failure to comply with financial and restrictive covenants in our credit agreement or restrictions on our operational and financial flexibility due to such covenants;

•the outcome of ongoing and future litigation, including our asbestos-related product liability litigation;

•changes in environmental laws and regulations applicable to our business; and

•disruptions in, or breaches of, our information technology systems.

Our forward-looking statements are expressly qualified by these cautionary statements, which you should consider carefully, along with the risks discussed in this section and elsewhere in this report, including under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 (the Annual Report) and our other reports filed with the SEC, any of which could cause actual results to differ materially from historical results or anticipated results. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes that appear elsewhere in this Form 10-Q along with our audited consolidated financial statements and the related notes thereto in our Annual Report.

Company Overview and Strategy

We design, develop, manufacture and sell high-performance and high-reliability engineered materials and components to meet our customers’ demanding challenges. We operate two strategic operating segments: AES and EMS. Our remaining operations, which represent non-core businesses, are reported in our Other operating segment. We are headquartered in Chandler, Arizona.

Our growth and profitability strategy is based upon the following principles: (1) market-driven organization, (2) innovation leadership, (3) synergistic mergers and acquisitions, and (4) operational excellence. Our priorities in executing this strategy are focused on driving near-term improvements to profitability and improving the growth outlook for the Company over the next several years by further strengthening our focus on commercial activities, expanding capacity to meet customer demand and driving innovation.

As a market-driven organization, we are focused on capitalizing on growth opportunities in the increasing electrification of vehicles, including EV/HEV, and increasing use of ADAS in the automotive industry, the advancement of communication systems in aerospace and defense, the growth of 5G smartphones in the portable electronics industry, and in renewable energy. In addition to our focus on these markets, we sell into a variety of other markets including general industrial, wireless infrastructure and mass transit.

Our growth strategy is based on addressing trends in these markets and applying our repeatable customer engagement process. Our sales engineers and technical service employees work closely with our customers to understand their complex challenges. They then leverage our innovation and technology capabilities and deep applications expertise to provide unique solutions to customers’ challenges. In addition to these capabilities, our strategy for success as a manufacturer of engineered materials and components is also built on our reputation for high performance and reliability solutions, trusted customer relationships, a broad product portfolio and custom design capabilities. Through this strategy we expect to be able to drive further commercial wins, which provide the potential for higher growth in the future. We have also expanded our capabilities through organic investment and acquisitions and strive to ensure high quality solutions for our customers.

Our operational excellence efforts are focused on driving significant near-term enhancements to our profitability and ongoing cost structure improvements. These efforts include focusing on improving yields, throughput, procurement capabilities and manufacturing processes and selectively adding strategic new hires to achieve better performance. We have also taken specific cost improvement actions in recent quarters that have benefited our performance. These actions include optimizing our manufacturing footprint, divesting non-core product lines and reductions to manufacturing and corporate employees. We continue to review and re-align our manufacturing and engineering footprint in an effort to maintain a leading competitive position globally and to support our customers’ growth initiatives.

We seek to enhance our operational and financial performance by investing in research and development, manufacturing and materials efficiencies, and new product initiatives that respond to the needs of our customers. We strive to evaluate operational and strategic alternatives to improve our business structure and align our business with the changing needs of our customers and major industry trends affecting our business.

If we are able to successfully execute on our strategy, we see an opportunity, over the next several years, to return to historical levels of profitability and meaningfully improve revenues from current levels, led by organic growth and complemented by targeted acquisitions. This outlook is supported by our participation in a number of growth markets and by our competitive positions in these markets. The fastest growing market opportunity is expected to be EV/HEV where third-party analysis

projects that the market will increase at a compound annual growth rate of between 15% and 20% over the next several years. Within the EV/HEV market, we believe our advanced battery cell pads and ceramic substrates provide multiple content opportunities to capitalize on this growth. Across these areas we have secured a number of design wins and have a strong opportunity pipeline. Other markets with good growth trajectories include ADAS, aerospace and defense, portable electronics and renewable energy.

Executive Summary

The following key highlights and factors should be considered when reviewing our results of operations, financial position and liquidity:

•In the third quarter of 2024 as compared to the third quarter of 2023, our net sales decreased approximately 8.2% to $210.3 million, our gross margin increased approximately 10 basis points to 35.2% from 35.1%, and we had an operating margin of 6.9% compared to an operating margin of 11.8%, a decrease of approximately 490 basis points.

•We made $30.0 million of discretionary principal payments on our revolving credit facility in the first quarter of 2024.

•We recognized restructuring charges of $5.9 million in the third quarter of 2024 in connection to our manufacturing footprint consolidation plan that is expected to be completed in the second half of 2025.

•We recognized restructuring charges of $0.4 million in the third quarter of 2024 in connection to our plan to exit our Burlington, Massachusetts Innovation Center facility that is expected to be completed by the end of 2024.

Results of Operations

The following table sets forth, for the periods indicated, selected operations data expressed as a percentage of net sales:


	Three Months Ended				Nine Months Ended
	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net sales	100.0	%	100.0	%	100.0	%	100.0	%
Gross margin	35.2	%	35.1	%	33.8	%	34.1	%

Selling, general and administrative expenses	21.4	%	19.4	%	22.5	%	21.4	%
Research and development expenses	3.9	%	3.4	%	4.2	%	3.6	%
Restructuring and impairment charges	3.0	%	0.8	%	1.2	%	2.3	%
Other operating (income) expense, net	—	%	(0.3)	%	—	%	(1.0)	%
Operating income	6.9	%	11.8	%	5.9	%	7.8	%

Equity income in unconsolidated joint ventures	0.2	%	0.3	%	0.2	%	0.2	%
Other income (expense), net	(0.7)	%	0.3	%	(0.1)	%	—	%
Interest expense, net	—	%	(1.0)	%	(0.2)	%	(1.2)	%
Income before income taxes	6.4	%	11.4	%	5.8	%	6.8	%
Income tax expense	1.3	%	3.1	%	1.6	%	2.1	%
Net income	5.1	%	8.3	%	4.2	%	4.7	%


Net Sales and Gross Margin
	Three Months Ended						Nine Months Ended
(Dollars in millions)	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023
Net sales	$	210.3		$	229.1		$	637.9		$	703.8
Gross margin	$	74.1		$	80.4		$	215.4		$	239.7
Percentage of net sales	35.2		%	35.1		%	33.8		%	34.1		%

Net sales decreased by 8.2% in the third quarter of 2024 compared to the third quarter of 2023. Our AES and EMS operating segments had net sales decreases of 11.2% and 3.9%, respectively. The decrease in net sales was primarily due to lower net sales in the EV/HEV, industrial power systems, ADAS and renewable energy markets in our AES operating segment and lower net sales in the aerospace and defense and portable electronics markets in our EMS operating segment. The decrease was partially offset by higher net sales in the wireless infrastructure and aerospace and defense markets in our AES operating segment and higher net sales in the EV/HEV market in our EMS operating segment. We experienced lower EV/HEV net sales in our AES operating segment as customers continued to manage inventory levels and adjusted to softer end market demand.

Net sales decreased by 9.4% in the first nine months of 2024 compared to the first nine months of 2023. Our AES and EMS operating segments had net sales decreases of 10.9% and 7.1%, respectively. The decrease in net sales was primarily due to lower net sales in the EV/HEV, ADAS, industrial power systems and renewable energy markets in our AES operating segment and lower net sales in the general industrial and aerospace and defense markets in our EMS operating segment. The decrease was partially offset by higher net sales in the wireless infrastructure and aerospace and defense markets in our AES operating segment and higher net sales in the EV/HEV market in our EMS operating segment. We experienced lower EV/HEV net sales in our AES operating segment as customers continued to manage inventory levels and adjusted to softer end market demand.

Gross margin as a percentage of net sales increased approximately 10 basis points to 35.2% in the third quarter of 2024 compared to 35.1% in the third quarter of 2023. Gross margin in the third quarter of 2024 improved due to favorable scrap and yield performance in our AES and EMS operating segments, less manufacturing spend from our factory optimization efforts in our AES operating segment, as well as favorable impacts in factory utilization and lower inventory reserves provisions in our EMS operating segment, partially offset by unfavorable impacts from lower volume and unfavorable mix in our AES and EMS operating segments.

Gross margin as a percentage of net sales decreased approximately 30 basis points to 33.8% in the first nine months of 2024 compared to 34.1% in the first nine months of 2023. Gross margin in the first nine months of 2024 declined due to unfavorable impacts from lower volume and unfavorable mix in our AES and EMS operating segments, as well as unfavorable factory utilization in our AES operating segment. This was partially offset by favorable scrap and yield performance and lower raw material costs in our AES and EMS operating segments, as well as favorable impacts in factory utilization and lower inventory reserves provisions in our EMS operating segment.


Selling, General and Administrative Expenses
	Three Months Ended						Nine Months Ended
(Dollars in millions)	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023
Selling, general and administrative expenses	$	45.1		$	44.2		$	143.5		$	150.5
Percentage of net sales	21.4		%	19.4		%	22.5		%	21.4		%

SG&A expenses increased 2.0% in the third quarter of 2024 from the third quarter of 2023, primarily due to a $0.8 million increase in software costs and a $0.2 million increase in recruiting, relocation and training expenses and a $0.1 million increase in fixed asset depreciation expense, as well as the non-recurrence of the $0.7 million gain on the sale of our high-performance engineered cellular elastomer business in 2023, partially offset by a $0.5 million decrease in professional services expense, a $0.5 million decrease in compensation and benefits expense and a $0.3 million decrease in other intangible asset amortization expense.

SG&A expenses decreased 4.7% in the first nine months of 2024 from the first nine months of 2023, primarily due to an $7.9 million decrease in professional services expense, a $1.0 million decrease in recruiting, relocation and training expenses and a $0.7 million decrease in other intangible asset amortization expense, partially offset by a $0.8 million increase in compensation and benefits expense, a $1.3 million increase in software costs and a $0.4 million increase in fixed asset depreciation expense, as well as the non-recurrence of the $0.7 million gain on the sale of our high-performance engineered cellular elastomer business in 2023. The decrease in professional services expense was primarily attributable to the non-recurrence of the $7.6 million of non-routine shareholder advisory costs and $1.1 million of expenses in connection with the sale of our high-performance engineered cellular elastomer business.


Research and Development Expenses
	Three Months Ended						Nine Months Ended
(Dollars in millions)	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023
Research and development expenses	$	8.1		$	7.8		$	26.5		$	25.5
Percentage of net sales	3.9		%	3.4		%	4.2		%	3.6		%

R&D expenses increased 3.8% in the third quarter of 2024 from the third quarter of 2023 due to a $0.7 million increase in trial costs for alternative raw materials, a $0.4 million increase in professional services expense and a $0.1 million increase in fixed assets depreciation expense, partially offset by a $0.4 million decrease in compensation and benefits expense.

R&D expenses increased 3.9% in the first nine months of 2024 from the first nine months of 2023 due to a $1.8 million increase in trial costs for alternative raw materials and a $0.5 million increase in fixed assets depreciation expense, partially offset by a $0.7 million decrease in compensation and benefits expense.


Restructuring and Impairment Charges and Other Operating (Income) Expense, Net
	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Restructuring and impairment charges	$	6.3	$	2.0	$	7.8	$	16.4
Other operating (income) expense, net	$	—	$	(0.8)	$	—	$	(7.5)

We incurred restructuring charges and related expenses in 2024 associated with our announced intent to wind down manufacturing operations in our Evergem, Belgium facility for our AES operating segment and our announced exit from our Burlington, Massachusetts Innovation Center facility. We recognized restructuring charges and related expenses pertaining to these restructuring plans of $6.3 million and $7.6 million in the three and nine months ended September 30, 2024.

We incurred restructuring charges and related expenses in 2024 and 2023 associated with the announced reduction of our global workforce along with certain facility consolidation efforts, which were substantially completed as of December 31, 2023. The plans significantly reduced our manufacturing costs and operating expenses. We recognized restructuring charges and related expenses pertaining to these restructuring projects of an immaterial amount and $0.2 million in the three and nine months ended September 30, 2024, respectively, and $2.0 million and $16.4 million in the three and nine months ended September 30, 2023, respectively. For additional information, refer to “Note 14 – Supplemental Financial Information” to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.

With respect to other operating (income) expense, net, we recognized no income and income of $0.8 million in the third quarter of 2024 and 2023, respectively, and no income and income of $7.5 million in the first nine months of 2024 and 2023, respectively. The impact in the second quarter and first nine months of 2023 primarily consisted of insurance recoveries, partially offset by professional service costs, from the fire at our UTIS manufacturing facility in Ansan, South Korea. For additional information, refer to “Note 14 – Supplemental Financial Information” to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.


Equity Income in Unconsolidated Joint Ventures
	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Equity income in unconsolidated joint ventures	$	0.4	$	0.6	$	1.2	$	1.5

As of September 30, 2024, we had two unconsolidated joint ventures, each 50% owned: RIC and RIS. Equity income in those unconsolidated joint ventures decreased $0.2 million in the third quarter of 2024 from the third quarter of 2023 and decreased $0.3 million in the first nine months of 2024 from the first nine months of 2023. On a quarter-to-date basis and a year-to-date basis, the decrease was due to lower net sales and unfavorable operational performance for RIS, partially offset by higher net sales and lower SG&A costs for RIC. The higher net sales for RIC was primarily driven by the portable electronics market in Asia.


Other Income (Expense), Net
	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023

Other income (expense), net	$	(1.5)	$	0.7	$	(0.8)	$	—

Other income (expense), net decreased to expense of $1.5 million in the third quarter of 2024 from income of $0.7 million in the third quarter of 2023. On a quarter-to-date basis, the decrease was due to an unfavorable year-over-year change in impacts from our foreign currency transactions and an unfavorable year-over-year change in impacts from our foreign currency derivatives, partially offset by a favorable year-over-year change in impacts from our copper derivative contracts.

Other income (expense), net decreased to expense of $0.8 million in the first nine months of 2024 from income of less than $0.1 million in the first nine months of 2023. On a year-to-date basis, the decrease was due to an unfavorable year-over-year change in impacts from our foreign currency derivatives, partially offset by a favorable year-over-year change in impacts from our foreign currency transactions and a favorable year-over-year change in impacts from our copper derivative contracts.


Interest Expense, Net
	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Interest expense, net	$	—	$	(2.3)	$	(1.0)	$	(8.6)

Interest expense, net, decreased by $2.3 million in the third quarter of 2024 from the third quarter of 2023, and decreased by $7.6 million in the first nine months of 2024 from the first nine months of 2023. The decreases on a year-over-year quarter-to-date basis and a year-to-date basis were primarily due to a lower weighted-average outstanding borrowings under our revolving credit facility.


Income Taxes
	Three Months Ended						Nine Months Ended
(Dollars in millions)	September 30, 2024			September 30, 2023			September 30, 2024			September 30, 2023
Income tax expense	$	2.8		$	7.2		$	10.4		$	14.3
Effective tax rate	20.7		%	27.3		%	28.1		%	30.0		%

The below discussion of the effective tax rate for the periods presented in the consolidated statements of operations is in comparison to the 21% U.S. statutory federal income tax rate.

Operating Segment Net Sales and Operating Income

Advanced Electronics Solutions


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net sales	$	112.2	$	126.3	$	349.8	$	392.4
Operating income	$	0.3	$	5.7	$	7.7	$	6.0

AES net sales decreased by 11.2% in the third quarter of 2024 compared to the third quarter of 2023. The decrease in net sales over the third quarter of 2023 was primarily driven by lower net sales in the EV/HEV, industrial power systems, ADAS and renewable energy markets, partially offset by higher net sales in the wireless infrastructure and aerospace and defense markets. We experienced lower EV/HEV net sales as customers continued to manage inventory levels and adjusted to softer end market demand.

AES net sales decreased by 10.9% in the first nine months of 2024 compared to the first nine months of 2023. The decrease in net sales over the first nine months of 2023 was primarily driven by lower net sales in the EV/HEV, ADAS, industrial power systems and renewable energy markets, partially offset by higher net sales in the wireless infrastructure and aerospace and defense markets. We experienced lower EV/HEV net sales as customers continued to manage inventory levels and adjusted to softer end market demand.

We recognized operating income of $0.3 million in the third quarter of 2024 compared to an operating income of $5.7 million in the third quarter of 2023. The decrease in operating income was primarily due to a $4.5 million unfavorable year-over-year change in restructuring charges, unfavorable impacts from lower volume and unfavorable mix and unfavorable factory utilization. The decrease in operating income was partially offset by favorable scrap and yield performance. As a percentage of net sales, the operating income in the third quarter of 2024 was 0.3% compared to 4.5% of operating income reported in the third quarter of 2023.

We recognized operating income of $7.7 million in the first nine months of 2024 compared to operating income of $6.0 million in the first nine months of 2023. The increase in operating income was primarily due to a $3.0 million favorable year-over-year change in restructuring charges, as well as favorable scrap and yield performance and lower raw material costs. The increase in operating income was partially offset by unfavorable impacts from lower volume and unfavorable mix as well as unfavorable factory utilization. As a percentage of net sales, operating income in the first nine months of 2024 was 2.2% compared to 1.5% of operating income reported in the first nine months of 2023.

Elastomeric Material Solutions


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net sales	$	94.2	$	98.0	$	274.6	$	295.6
Operating income	$	13.2	$	19.9	$	25.7	$	43.3

EMS net sales decreased by 3.9% in the third quarter of 2024 compared to the third quarter of 2023. The decrease in net sales over the third quarter of 2023 was primarily driven by lower net sales in the aerospace and defense and portable electronics markets, partially offset by higher net sales in the EV/HEV market.

EMS net sales decreased by 7.1% in the first nine months of 2024 compared to the first nine months of 2023. The decrease in net sales over the first nine months of 2023 was primarily driven by lower net sales in the general industrial and aerospace and defense markets, partially offset by higher net sales in the EV/HEV market.

We recognized operating income of $13.2 million in the third quarter of 2024 compared to operating income of $19.9 million in the third quarter of 2023. The decrease in operating income was due to a $0.6 million unfavorable year-over-year change in charges/benefits related to the UTIS fire, higher general and administrative expenses due to our capacity expansion efforts in Suzhou, China, higher trial costs for alternative raw materials and the non-recurrence of the $0.7 million gain on the sale of our high-performance engineered cellular elastomer business in 2023, as well as unfavorable impacts from lower volume and unfavorable mix. The decrease in operating income was partially offset by a $0.2 million favorable year-over-year change in restructuring charges, favorable scrap and yield performance, favorable impacts in factory utilization and lower inventory reserves provisions. As a percentage of net sales, operating income in the third quarter of 2024 was 14.0% compared to an operating income of 20.3% reported in the third quarter of 2023.

We recognized operating income of $25.7 million in the first nine months of 2024 compared to operating income of $43.3 million in the first nine months of 2023. The decrease in operating income was due to a $6.8 million unfavorable year-over-year change in charges/benefits related to the UTIS fire, higher general and administrative expenses due to our capacity expansion efforts in Suzhou, China, higher trial costs for alternative raw materials and the non-recurrence of the $0.7 million gain on the sale of our high-performance engineered cellular elastomer business in 2023, as well as unfavorable impacts from lower volume and unfavorable mix. The decrease in operating income was partially offset by a $5.6 million favorable year-over-year change in restructuring charges, as well as favorable scrap and yield performance, favorable impacts in factory utilization, lower raw material costs and lower inventory reserves provisions. As a percentage of net sales, operating income in the first nine months of 2024 was 9.4% compared to 14.6% reported in the first nine months of 2023.

Other


	Three Months Ended				Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023		September 30, 2024		September 30, 2023
Net sales	$	3.9	$	4.8	$	13.5	$	15.8
Operating income	$	1.1	$	1.6	$	4.2	$	5.5

Net sales in this segment decreased by 18.8% in the third quarter of 2024 from the third quarter of 2023. Operating income decreased 31.3% in the third quarter of 2024 compared to the third quarter of 2023. The decrease in operating income was primarily driven by unfavorable impacts from lower volume. As a percentage of net sales, the operating income in the third quarter of 2024 was 28.2% compared to an operating income of 33.5% reported in the third quarter of 2023.

Net sales in this segment decreased by 14.6% in the first nine months of 2024 from the first nine months of 2023. Operating income decreased 23.6% in the first nine months of 2024 compared to the first nine months of 2023. The decrease in operating income was primarily driven by unfavorable impacts from lower volume and unfavorable factory utilization. As a percentage of net sales, operating income in the first nine months of 2024 was 31.1% compared to 34.6% in the first nine months of 2023.

Liquidity, Capital Resources and Financial Position

We believe that our existing sources of liquidity and cash flows that we expect to generate from our operations, together with our available credit facilities, will be sufficient to fund our operations, currently planned capital expenditures, research and

development efforts and our debt service commitments, for at least the next 12 months. We regularly review and evaluate the adequacy of our cash flows, borrowing facilities and banking relationships in an effort to ensure that we have the appropriate access to cash to fund both our near-term operating needs and our long-term strategic initiatives.

The following table illustrates the location of our cash and cash equivalents by our three major geographic areas:


(Dollars in millions)	September 30, 2024		December 31, 2023
United States	$	52.9	$	60.0
Europe	40.0		37.6
Asia	53.5		34.1
Total cash and cash equivalents	$	146.4	$	131.7

Approximately $93.5 million of our cash and cash equivalents were held by non-U.S. subsidiaries as of September 30, 2024. We did not make any changes in the nine months ended September 30, 2024 to our position on the permanent reinvestment of our earnings from foreign operations. With the exception of certain of our Chinese subsidiaries, where a substantial portion of our Asia cash and cash equivalents are held, we continue to assert that historical foreign earnings are indefinitely reinvested.


(Dollars in millions)	September 30, 2024		December 31, 2023
Key Financial Position Accounts:
Cash and cash equivalents	$	146.4	$	131.7
Accounts receivable, net	$	156.3	$	161.9
Inventories, net	$	154.4	$	153.5
Borrowings under revolving credit facility	$	—	$	30.0

Changes in key financial position accounts and other significant changes in our statements of financial position from December 31, 2023 to September 30, 2024 were as follows:

•Cash and cash equivalents were $146.4 million as compared to $131.7 million as of December 31, 2023, an increase of $14.7 million, or 11.2%. This increase was primarily due to cash flows provided by operations, partially offset by $30.0 million in discretionary principal payments on our revolving credit facility, $40.7 million in capital expenditures, $7.9 million in share repurchases and $1.3 million in tax payments related to net share settlement of equity awards.

•Accounts receivable, net decreased 3.5% to $156.3 million as of September 30, 2024 from $161.9 million as of December 31, 2023. The decrease from year-end was primarily due to a $4.1 million receipt of previously recognized UTIS fire insurance receivables for our business interruption claims and a $1.5 million decrease in our income taxes receivable.

•Inventories, net increased 0.6% to $154.4 million as of September 30, 2024, from $153.5 million as of December 31, 2023, primarily driven by higher finished goods and raw materials levels, partially offset by higher inventory reserves provisions.

•Borrowings under revolving credit facility were nil as of September 30, 2024 compared to $30.0 million as of December 31, 2023. This decrease was due to $30.0 million in discretionary principal payments on our revolving credit facility made in the first three months of 2024. For additional information regarding this facility and the Fifth Amended Credit Agreement, refer to “Note 9 – Debt” to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.


	Nine Months Ended
(Dollars in millions)	September 30, 2024		September 30, 2023
Key Cash Flow Measures:
Net cash provided by operating activities	$	93.4	$	59.5
Net cash used in investing activities	$	(40.7)	$	(30.3)
Net cash used in financing activities	$	(38.6)	$	(139.6)

In 2024, we expect capital spending to be in the range of approximately $50.0 million to $60.0 million. We plan to fund our capital spending in 2024 with cash from operations and cash on-hand, as well as our existing revolving credit facility, if necessary.

Restrictions on Payment of Dividends

The Fifth Amended Credit Agreement generally permits us to pay cash dividends to our shareholders, provided that (i) no default or event of default has occurred and is continuing or would result from the dividend payment and (ii) our total net leverage ratio does not exceed 2.75 to 1.00. If our total net leverage ratio exceeds 2.75 to 1.00, we may nonetheless make up to $20.0 million in restricted payments, including cash dividends, during the fiscal year, provided that no default or event of default has occurred and is continuing or would result from the payments. Our total net leverage ratio did not exceed 2.75 to 1.00 as of September 30, 2024.

Contingencies

During the third quarter of 2024, we did not become aware of any material developments related to environmental matters disclosed in our Annual Report, our asbestos litigation or other material contingencies previously disclosed or incur any material costs or capital expenditures related to such matters. Refer to “Note 10 – Commitments and Contingencies” to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q for further discussion of these contingencies.

Critical Accounting Policies

There were no material changes in our critical accounting policies during the third quarter of 2024.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our exposure to market risk during the third quarter of 2024. For discussion of our exposure to market risk, refer to “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” contained in our Annual Report.

Item 4. Controls and Procedures

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We conducted, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d- 15(e) under the Exchange Act, as of September 30, 2024. Our disclosure controls and procedures are designed (i) to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2024.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes in the Company’s internal control over financial reporting during the third quarter of the fiscal year ended December 31, 2024, that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act.

Part II - Other Information

Item 1. Legal Proceedings

Refer to the discussion of certain environmental, asbestos and other litigation matters in “Note 10 – Commitments and Contingencies” to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Items 2 (a) and (b) are not applicable.

For the three months ended September 30, 2024, we repurchased no shares under a $200.0 million share repurchase program approved by our Board of Directors. The share repurchase program has no expiration date and may be suspended or discontinued at any time without notice. As of September 30, 2024, $116.2 million remained for repurchase under the share repurchase program. All repurchases are made using cash from operations. Our stock repurchases may occur from time to time through open market purchases, privately negotiated transactions or plans designed to comply with Rule 10b5-1 promulgated under the Exchange Act.

Item 5. Other Information

During the three months ended September 30, 2024, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.

Item 6. Exhibits


List of Exhibits:

10.1			Letter Agreement between the Company and Laura Russell, incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on August 12, 2024.

31.1			Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2			Certification of Vice President and Interim Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32			Certification of President and Chief Executive Officer (Principal Executive Officer) and Vice President and Interim Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

101			The following materials from Rogers Corporation’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and September 30, 2023, (ii) Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2024 and September 30, 2023, (iii) Condensed Consolidated Statements of Financial Position as of September 30, 2024 and December 31, 2023, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and September 30, 2023, (v) Condensed Consolidated Statements of Shareholders’ Equity for the three and nine months ended September 30, 2024 and September 30, 2023, (vi) Notes to Condensed Consolidated Financial Statements and (vii) Cover Page.

104			The cover page from Rogers Corporation’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, formatted in iXBRL and contained in Exhibit 101.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ROGERS CORPORATION (Registrant)


/s/ Laura Russell
Laura Russell
Vice President, Interim Chief Financial Officer and Treasurer
Principal Financial Officer
Dated: October 25, 2024

Get the next $ROG alert in real time by email

Date	Price Target	Rating	Analyst
3/14/2023	$185.00	Market Outperform	CJS Securities
2/14/2023	$180.00	Buy	B. Riley Securities
12/14/2021	$277.00	Market Outperform → Market Perform	CJS Securities
11/4/2021	$225.00 → $277.00	Buy → Hold	Stifel
11/4/2021	$233.00 → $277.00	Buy → Hold	Canaccord Genuity
11/3/2021		Outperform → Peer Perform	Wolfe Research
7/30/2021	$260.00 → $233.00	Buy	Canaccord Genuity

SEC Form 10-Q filed by Rogers Corporation

Chat with this insight

Recent Analyst Ratings for $ROG

$ROG Leadership Updates

Live Leadership Updates

Ram Mayampurath to Join MKS Instruments as Chief Financial Officer

Rogers Appoints Senior Vice President of Global Operations and Supply Chain

Rogers Announces Leadership Transition

$ROG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CJS Securities initiated coverage on Rogers Corp with a new price target

B. Riley Securities resumed coverage on Rogers Corp with a new price target

Rogers Corp downgraded by CJS Securities with a new price target

$ROG SEC Filings

SEC Form 10-Q filed by Rogers Corporation

Rogers Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Rogers Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

$ROG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP & Chief Admin Officer Webb Michael Reed sold $45,268 worth of Common Stock (416 units at $108.82), decreasing direct ownership by 9% to 4,400 units (SEC Form 4)

Interim CFO Russell Laura covered exercise/tax liability with 31 units of Capital Stock, decreasing direct ownership by 3% to 1,021 units (SEC Form 4)

New insider Russell Laura claimed ownership of 1,052 units of Capital Stock (SEC Form 3)

$ROG Press Releases

Fastest customizable press release news feed in the world

$ROG Financials

Live finance-specific insights

$ROG Large Ownership Changes

This live feed shows all institutional transactions in real time.

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Rogers Corporation Reports Third Quarter 2024 Results

Roche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

Rogers Corporation Reports Third Quarter 2024 Results

Rogers Corporation Schedules Third Quarter 2024 Earnings Call for October 24

Rogers Corporation Reports Second Quarter 2024 Results

Amendment: SEC Form SC 13G/A filed by Rogers Corporation

SEC Form SC 13G/A filed by Rogers Corporation (Amendment)

SEC Form SC 13G filed by Rogers Corporation

$ROG Market Insights

Live Market Insights

Rogers Plans To Streamline Operations; Intends To Wind Down Manufacturing Of Advanced Circuit Materials And Other Related Activities At Its Evergem, Belgium Factory By Mid-2025

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday

Recent Analyst Ratings for
$ROG

$ROG
Leadership Updates

$ROG
Analyst Ratings

$ROG
SEC Filings

$ROG
Insider Trading

$ROG
Press Releases

$ROG
Financials

$ROG
Large Ownership Changes

$ROG
Market Insights